

Table of Contents 2

List of Tables & Charts 3

Study Overview 4

Sample Text, Table & Chart **5**

Sample Profile, Table &

Forecast 6

Order Form 7

About Freedonia, Custom Research, Related Studies, Corporate Use License 8



In Vitro Diagnostics

US Industry Study with Forecasts for 2013 & 2018

Study #2455 | March 2009 | \$4800 | 373 pages



The Freedonia Group

767 Beta Drive

Cleveland, OH • 44143-2326 • USA

Toll Free US Tel: 800.927.5900 or +1 440.684.9600

Fax: +1 440.646.0484

E-mail: info@freedoniagroup.com

US Industry Study with Forecasts for 2013 & 2018



Table of Contents

EXECUTIVE SUMMARY

MARKET ENVIRONMENT

General	4
Macroeconomic Environment	
Population & Demographic Trends	10
Health Care Trends	
Acute Conditions	
Chronic Conditions	10
Cancer & AIDS	
Health Insurance Trends	2
National Health Expenditures	2!
Medical Providers	
Acute Care Hospitals	28
Physicians	2
Outpatient Facilities	30
Patient Activity	
Hospital Activity	
Surgical Procedures	
Outpatient & Home Health Care Activity	
IVD Product Overview	
Regulation	
Technology	
Diagnostic Testing Volume	
Clinical Laboratory Testing Services	
Pricing Trends	
Product Demand Patterns, 1998-2008	
US Trade	
International Markets	50

IVD PRODUCTS	
General	5
Product Segments	
Reagents & Consumables	5
Instruments & Systems	
Clinical Chemistry Products	6
Professional Products	
Reagents & Test Kits	6
Blood Glucose	6
Lipids	
Electrolytes & Blood Gases	6
Proteins	
Enzymes	
Toxicology Reagents	
Other Clinical Chemistry Reagents	
Standards & Controls	
Instruments & Systems	
Applications	
Producers	
Self-Testing Products	
Blood Glucose Monitoring Products	
Test Strips & Discs	
Monitors	
Other Self-Testing Products	
Immunoassay Products	
Technology Overview	
Competitive Immunoassays	
Noncompetitive Immunoassays	
Heterogeneous & Homogeneous Immunoassays	
Labeling Techniques	
Manual Immunoassays 1	0

Reagents & Test Kits	
Enzyme Immunoassays	
Chemiluminescent Immunoassays	
Fluorescent Immunoassays	10
Radioimmunoassays	
Instruments & Systems	
Applications	
Drug Testing	10
Therapeutic Drugs	
Illicit Drugs	
Infectious Disease Testing	
Endocrine Condition Testing	10
Cancer Testing	10
Heart Disease Testing	11
Other Applications	11
Producers	11
Blood Testing Products	
Hematology Products	
Reagents & Consumables	
Instruments & Systems	11
Applications	11
Producers	
Blood Banking Products	12
Reagents & Consumables	
Instruments & Systems	
Applications	
Producers	12
Hemostasis Products	12
Reagents & Consumables	12
Instruments & Systems	12
Applications	
Producers	
Nucleic Acid Testing Products	
Technology Overview	
Polymerase Chain Reaction (PCR)	13
Microarrays	13
DNA Sequencing	
	12
In Situ Hybridization (ISH)	13 14
In Situ Hybridization (ISH)	14
Restriction Fragment Length	14
Restriction Fragment Length Polymorphisms (RFLPs)	14 14
Restriction Fragment Length Polymorphisms (RFLPs)Amplified DNA Probes	14 14 14
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes	14 14 14 14
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems	14 14 14 14
Restriction Fragment Length Polymorphisms (RFLPs)	14 14 14 14 14
Restriction Fragment Length Polymorphisms (RFLPs)	14 14 14 14 14
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products	14 14 14 14 14 14
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays	14 14 14 14 14 14 14
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications	14 14 14 14 14 14 15 15
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management	14 14 14 14 14 15 15
Restriction Fragment Length Polymorphisms (RFLPs)	14 14 14 14 14 15 15 15
Restriction Fragment Length Polymorphisms (RFLPs)	14 14 14 14 14 15 15 15 15
Restriction Fragment Length Polymorphisms (RFLPs)	14 14 14 14 14 15 15 15 15
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications	14 14 14 14 14 15 15 15 15 15
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers	14 14 14 14 14 15 15 15 15 15
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers Microbiology Products	14 14 14 14 14 15 15 15 15 15 15
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers Microarray Products Under Media	14 14 14 14 14 15 15 15 15 15 15 16
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing. Consumables Applications Producers Microbiology Products. Culture Media Reagents & Consumables	14 14 14 14 14 15 15 15 15 15 16 16
Restriction Fragment Length Polymorphisms (RFLPs)	14 14 14 14 14 15 15 15 15 16 16
Restriction Fragment Length Polymorphisms (RFLPs)	14 14 14 14 14 15 15 15 15 16 16 16
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers Microbiology Products. Culture Media Reagents & Consumables Instruments & Systems Applications Producers Applications Producers Instruments & Systems Applications Producers Producers	14 14 14 14 14 15 15 15 15 15 16 16 16 16
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers Microbiology Products Culture Media Reagents & Consumables Instruments & Systems Applications Producers Culture Media Regents & Consumables Instruments & Systems Applications Producers Cellular Analysis Products	14 14 14 14 14 15 15 15 15 16 16 16 16 16
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers Microbiology Products Culture Media Reagents & Consumables Instruments & Systems Applications Producers Cellular Analysis Products Flow Cytometry Products	14 14 14 14 14 15 15 15 15 15 16 16 16 16 16 16
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers Microbiology Products Culture Media Reagents & Consumables Instruments & Systems Applications Producers Cellular Analysis Products Flow Cytometry Products Reagents & Consumables Reagents & Consumables Flow Cytometry Products Reagents & Consumables	14 14 14 14 14 15 15 15 15 15 16 16 16 16 16 16
Restriction Fragment Length Polymorphisms (RFLPs) Amplified DNA Probes Direct DNA Probes Instruments & Systems PCR Systems Microarray Systems Microarray Products Types of Microarrays IVD Applications Disease Management Forensic Medicine Illicit Drug Testing Consumables Applications Producers Microbiology Products Culture Media Reagents & Consumables Instruments & Systems Applications Producers Cellular Analysis Products Flow Cytometry Products	14 14 14 14 14 15 15 15 15 15 16 16 16 16 16 16 16

Other Cellular Analysis Products	172
Reagents & Consumables	
Instruments	
Applications	176
Producers	177
Other IVD Products	177
Anatomical Pathology Products	178
Histology Products	179
Immunohistochemistry Products	181
Effusion & Visual Inspection Products	183
Visual Inspection Tests	184
Effusion Tests	185
Applications	186
Producers	187
Cytology Products	190
Reagents, Supplies & Instruments	191
Applications	193

IVD APPLICATIONS

General	195
Endocrine Conditions	
Diabetes Monitoring Products	190
Blood Glucose Test Strips	
Blood Glucose Monitors	
Other Diabetes Monitoring Products	
Hemoglobin A1c	
Microalbumin	204
Ketones	
All Other Diabetes IVD Products	
Pregnancy, Ovulation & Fertility Tests	
Other IVD Products for Endocrine Conditions	
Infectious Diseases	
Sexually Transmitted Diseases	
IVD Demand by Methodology	211
IVD Demand by Condition	212
AIDS/HIV	213
Chlamydia	
Herpes	218
Gonorrhea	
Other Sexually Transmitted Diseases	
Other Infectious Diseases	220
IVD Demand by Methodology	220
IVD Demand by Condition	221
Hepatitis	222
All Other Infectious Diseases	
Cancer	
IVD Demand by Methodology	227
IVD Demand by Condition	228
Cervical Cancer	
Breast Cancer	
Prostate Cancer	
Colorectal Cancer	
Other Cancers	
Drug Testing	236
Therapeutic Drug Monitoring (TDM)	238
Illicit Drug Testing	240
Heart Disease	
Lipid Profiling	245
Cardiac Markers	
Blood Proteins	
Blood Grouping & Screening	248
Blood Typing & Matching	
Blood & Bleeding Disorders	25(
(continued on next nage)	

US Industry Study with Forecasts for 2013 & 2018



Table of Contents

(continued from previous page)

List of Tables/Charts

251 252 252 254 256 256 256
264 264 269 270 272
274 277 284 285 296 296
301 306 308 313 313 313 313 313 313 313 313 313 31

EXI	ECUTIVE SUMMARY
1	Summary Table3
VI <i>P</i>	ARKET ENVIRONMENT
1	Macroeconomic Indicators
2	Population & Demographics
3	Acute Conditions by Type16
4	Chronic Conditions by Type 18
5	Cancer & AIDS Indicators
6	Health Insurance Coverage of the
-	US Population, 1998-2008
7	National Health Expenditures by Type & Source 27
8	Acute Care Hospitals
9 10	Outpatient Facilities
11	Acute Care Hospital Activity
12	Surgical Procedures
13	Outpatient & Home Health Care Activity 36
14	Diagnostic Testing Volume
15	Clinical Laboratory Testing Sites & Revenues 45
16	IVD Product Demand, 1998-2008
17	US Trade in IVD Products 50
18	World IVD Product Demand by Region53
VE	PRODUCTS
1	IVD Demand by Product Group 56
Cht	IVD Product Demand by Methodology, 2008 58
2	IVD Product Demand by Methodology 58
3	IVD Reagent & Consumable
	Demand by Methodology61
4	IVD Instrument & System
_	Demand by Methodology
5 6	Clinical Chemistry Product Demand by Segment 65 Professional Clinical Chemistry Product
U	Demand by Type
7	Common Clinical Chemistry Tests
8	Professional Clinical Chemistry Product
	Demand by Application85
9	Self-Testing Clinical Chemistry Product
	Demand by Type 87
10	Self-Testing Clinical Chemistry Product
	Demand by Application94
11	Immunoassay Product Demand by Type 96
12	Immunoassay Product Demand by Application 106
13	Blood Testing Product
1/	Demand by Methodology
14 15	Hematology Product Demand by Type
16	Blood Banking Product Demand by Type 122
17	Blood Banking Product Demand by Application 125
18	Hemostasis Product Demand by Type 128
19	Hemostasis Product Demand by Application 132
20	Nucleic Acid Testing Product Demand by Type 136
21	Nucleic Acid Testing Product
_	Demand by Application
22	Microbiology Product Demand by Type 160
23	Microbiology Product Demand by Application. 164
24	Cellular Analysis Product
	Demand by Methodology 166
25	Flow Cytometry Product Demand by Type 167
26	Flow Cytometry Product
	Demand by Application 170

27	Other Cellular Analysis Product	
28	Demand by Type Other Cellular Analysis Product	
	Demand by Application	176
29 30	Other IVD Product Demand by Methodology Anatomical Pathology Product	
31	Demand by Type	
32	Effusion & Visual Inspection Product	
33	Demand by Type	
27	Demand by Application	18
34 35	Cytology Product Demand by Application	194
IVE	APPLICATIONS	
1	IVD Product Demand by Application	196
Cht 2	IVD Product Demand by Application, 2008 Endocrine Testing IVD Product Demand	
_	by Methodology & Condition	198
3	Infectious Disease Testing IVD Product Demand by Condition	210
4	Sexually Transmitted Disease (STD) Testing	
5	IVD Product Demand by Methodology Sexually Transmitted Disease (STD) Testing	
6	IVD Product Demand by Condition Other Infectious Disease Testing IVD	
7	Demand by Methodology	22
	Demand by Methodology	228
8	Cancer Testing IVD Product Demand by Condition	229
9	Drug Testing IVD Product Demand by Methodology & Type	
10	Heart Disease Testing IVD Product Demand	
11	by Methodology	
12	Demand by Methodology Forensic & Related Testing IVD Product	249
	Demand by Methodology	252
13	Applications IVD Product Demand	
	by Methodology & Procedure	256
IVE	MARKETS	
1	IVD Product Demand by Market	263
	IVD Product Demand by Market, 2008	263
2	Hospital Laboratory IVD Product Demand	
3	Independent Clinical Laboratory IVD Product Demand	268
4	Home IVD Product Demand	270
5	Outpatient IVD Product Demand	
6	Other Markets: IVD Product Demand	273
INI	DUSTRY STRUCTURE	
1	US IVD Product Sales by Company, 2008	276
Cht	US IVD Product Sales, Market Share by Company, 2008	
	by company, 2000	L/

US Industry Study with Forecasts for 2013 & 2018



Clinical chemistry and immunoassay will remain the top two IVD methodologies, while nucleic acid testing products will generate the fastest demand gains among IVD products.

US demand to grow 5.4% annually through 2013

US demand for in vitro diagnostic (IVD) products is forecast to increase 5.4 percent annually to \$23 billion in 2013. Clinical chemistry and immunoassay will remain the top two IVD methodologies, the former based on sales of personal blood glucose monitors and test strips and the latter due to the penetration of high value-added chemiluminescent products into infectious disease and drug testing markets. Nucleic acid testing products will generate the fastest demand gains among IVD products based on throughput, accuracy and speed advantages, especially in the detection of infectious diseases and cancer markers. Because of increasing blood glucose monitoring among diabetic patients, endocrine condition testing will remain the largest IVD application through 2013 and beyond.

Evolving trends, care approaches to benefit most IVD products

Evolving epidemiological trends and patient care approaches will impact favorably on growth opportunities for most types of IVD products. The market for clinical chemistry reagents and instruments will benefit from an increasing number of diabetic patients engaging in self-blood glucose monitoring and the expanding use of general health screening in routine patient examinations. The



widening availability of chemiluminescent tests with inherent sensitivity and selectivity advantages will broaden applications for immunoassays in therapeutic drug monitoring, drugs of abuse detection and infectious disease testing.

Due to their ability to quantify heart attack and embolism risk prior to occurrence, hemostasis tests for D-dimer and other cardiac parameters will provide the best growth opportunities among IVD blood testing products. Demand for nucleic acid diagnostics will expand at a strong pace as next- generation PCR (polymerase chain reaction) and microarray technologies penetrate applications involving the analysis and charac-

terization of complex infections and tumors. DNA-based forensic, genetic and identity testing will comprise the fastest growing IVD application through 2013 as the vast potential of law enforcement and genetic screening markets begins to produce significant revenues. Among other IVD products, cellular analysis and anatomical pathology reagents and instruments will post favorable gains. Cellular analysis techniques will continue to dominate cervical cancer testing and penetrate additional cancer diagnostic applications. Anatomical pathology will remain the leading IVD technique for biopsy-based cancer and infectious disease detection.

Copyright 2009 The Freedonia Group, Inc.

US Industry Study with Forecasts for 2013 & 2018



Sample Text, Table & Chart

TABLE III-12

IMMUNOASSAY PRODUCT DEMAND BY APPLICATION (million dollars)

Item

Immunoassay Product Demand

Infectious Disease Testing:

Other Infectious Diseases

Sexually Transmitted Diseases

Therapeutic Drugs

Endocrine Conditions

Drug Testing:

Cancer

Other

Heart Disease

Illicit Drugs

1998 2003 2008 2013 2018

IVD PRODUCTS

Instruments & Systems

Nucleic acid instruments and systems are used to create reagents, amplify patient samples, test for reagent-sample rea analyze results. Demand for these products is forecast to inc

SAMPLE g to the doce and conpact of a ted a lar

million in 2013. Technological adv g to the development of upgraded ece and convenience capabilities. The pact of a maturing market for PCR ated a large percentage of available aboratory markets. New biochip seconds in the case of the

growth, but will serve more limited IVD ap-

plications due to competition from lower cost technologies.

PCR Systems -- One of the most advanced and versatile nucleic acid preparation systems is Roche Diagnostics' LIGHTCYCLER. The LIGHTCYCLER is a modified variable temperature block that separates and amplifies minute DNA particles from patient samples up to a million times to create probes detectable through laser-based or other imaging technologies. This system allows for real-time analysis of the amplification process to assure that enhanced probes match the structures of the starting DNA particles.

bioMerieux makes nucleic acid testing systems for detecting DNA or RNA gene sequences associated with various pathogens. Included in this line are NUCLISENS EASYQ automated systems for nucleic acid amplification and real-time molecular beacon detection; and NUCLISENS EASYMAG automated nucleic acid extraction equipment.


PCR analyzers utilize lasers to detect hybridization between amplified sample probes and enzyme-labeled reagent probes associated with a specific condition. Reagents are mixed with samples in the reaction chamber through the use of robotic arms. PCR has given rise to several

145 Copyright 2009 The Freedonia Group, Inc.

SAMPLE TABLE




US IVD PRODUCT SALES, MARKET SHARE BY COMPANY, 2008 (\$17.6 billion)



US Industry Study with Forecasts for 2013 & 2018



Sample Profile, Table & Forecast



COMPANY PROFILES

Meridian Bioscience Incorporated

3471 River Hills Drive Cincinnati, OH 45244 513-271-3700 http://www.n

Revenues: \$
Research and

Employment

Key Products

antigens, anti

SAMPLE PROFILE

ducts, bulk

2008)

Meridian Bioscience is a fully integrated life science company. The Company operates through three segments: US Diagnostics, European Diagnostics and Life Science.

Meridian Bioscience participates in the US *in vitro* diagnostic market via the US Diagnostics and Life Science segments. In FY 2008, the US Diagnostics segment generated revenues of \$88 million and employed 265. Through this segment, the Company develops and produces a broad range of rapid diagnostic test kits and related products at a plant in Cincinnati, Ohio. These products are mainly used in reference laboratories, hospitals and physicians' offices in the US and Canada.

Meridian Bioscience's rapid diagnostic test kits utilize various immunodiagnostic technologies -- such as enzyme immunoassay, immunofluorescence, particle agglutination and aggregation, immunodiffusion, complement fixation, and chemical stains -- to test samples of blood, urine, stool and other bodily fluids and tissues for markers of respiratory, gastrointestinal, viral, parasitic and other infectious diseases.

341 Copyright 2009 The Freedonia Group, Inc.

"IVD product demand in prostate cancer applications is projected to expand 4.3 percent annually to \$215 million in 2013. The condition's high survival rate, especially when detected in early stages, will promote growth by encouraging at-risk males to undergo periodic tumor screening procedures. Since the mid-1990s, the number of new prostate cancer cases has been declining due to the impact of healthier lifestyles and slow increases in the 65 years and older male population. Demand for IVD products in prostate cancer applications will benefit from ..." --Section IV, pq. 233

ORDER INFORMATION

Five Convenient Ways to Order

INDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERS



ONLINE: www.freedoniagroup.com

MAIL: Print out and complete the order form and send to The Freedonia Group (see address at the bottom of this form)

PHONE: Call toll free, 800.927.5900 (US) or +1 440.684.9600

FAX: +1 440.646.0484 (US)

EMAIL: info@freedoniagroup.com

Free Handling & Shipping

There is NO charge for handling or UPS shipping in the US. Expect delivery in 3 to 5 business days. Outside the US, Freedonia provides free airmail service. Express delivery is available at cost.

Orders Outside of the US

Checks must be made payable in US funds, drawn against a US bank and mailed directly to The Freedonia Group. For wire transfers please contact our customer service department at info@freedoniagroup.com. Credit cards accepted.

Credit Card Orders

For convenience, Freedonia accepts American Express, MasterCard or Visa. Credit card purchases must include account number, expiration date and authorized signature.

Save 15%

If you order three (3) different titles at the same time, you can receive a 15% discount. If your order is accompanied by a check or wire transfer, you may take a 5% cash discount (discounts do not apply to Corporate Use Licenses).

Corporate Use License

Now every decision maker in your organization can act on the key intelligence found in all Freedonia studies. For an additional \$2300, companies receive unlimited use of an electronic version (PDF) of the study. Place it on your intranet, e-mail it to coworkers around the world, or print it as many times as you like,

Click here to learn more about the Corporate Use License

ORDER FORM F-WEB.2455	Name
In Vitro Diagnostics\$4800	Title
Corporate Use License (add to study price) * + \$2300	Company
Additional Print Copies @ \$500 each * Total (including selected option) \$	Division
☐ Enclosed is my check (5% discount) drawn on a US bank and payable to The Freedonia Group, Inc., in US funds (Ohio residents add 7.75% sales tax)	Street (No PO Box please)
☐ Bill my company ☐ American Express ☐ MasterCard ☐ Visa	City/State/Zip
MM YY	Country
Credit Card # Expiration	Phone Fax
Signature	Email
* Please check appropriate option and sign below to order an electronic version of the study. Corporate Use License Agreement The above captioned study may be stored on the company's intranet or shared directory, available to company employees. Copies of the study may be made, but the undersigned represents that distribution of the study will be limited to employees of the company.	☐ Individual Use License Agreement The undersigned hereby represents that the above captioned study will be used by only individual(s) who are employees of the company and that the study will not be loaded on a network for multiple users. In the event that usage of the study changes, the Company will promptly notify Freedonia of such change and will pay to Freedonia the appropriate fee based on Freedonia's standard fee schedule then in effect. Note: Entire company corporate use license, add \$2300; one additional user, add \$500; two additional users, add \$1000; three additional users, add \$1500.
Signature	Signature

The Freedonia Group, Inc. 767 Beta Drive • Cleveland, OH • 44143-2326 • USA • Web site: www.freedoniagroup.com
Tel US: 800.927.5900 or +1 440.684.9600 • Fax: +1 440.646.0484 • e-mail: info@freedoniagroup.com



OTHER STUDIES

Home Medical Equipment

US demand for home medical equipment will grow 5.5% annually through 2012. Cost-saving products such as CPAP machines, peritoneal dialysis equipment, IV pumps, ventilators and BP monitors will lead gains. Mobility devices, medical furniture and home safety equipment will continue to form sizeable markets. This study analyzes the \$7.7 billion US home medical equipment industry, with forecasts for 2012 and 2017 by equipment type. It also evaluates market share and profiles industry players.

#2447.......01/2009......\$4600

Biochips

US demand for biochip products and services will grow nearly 10% annually through 2012. Growth will be led by uses in drug discovery and epidemiological research, with protein characterization and analysis providing the fastest expanding technologies. Contract research and outsourcing will post the strongest gains among biochip services. This study analyzes the \$1.6 billion US biochips industry, with forecasts for 2012 and 2017 by product, service, application and market. It also evaluates market share and profiles industry players.

Cosmeceuticals

Patient Monitoring Systems

Food Safety Products

About The Freedonia Group

The Freedonia Group, Inc., is a leading international industry market research company that provides its clients with information and analysis needed to make informed strategic decisions for their businesses. Studies help clients identify business opportunities, develop strategies, make investment decisions and evaluate opportunities and threats. Freedonia research is designed to deliver unibiased views and reliable outlooks to assist clients in making the right decisions. Freedonia capitalizes on the resources of its proprietary in-house research team of experienced economists, professional analysts, industry researchers and editorial groups. Freedonia covers a diverse group of industries throughout the United States, the emerging China market, and other world markets. Industries analyzed by Freedonia include:

Chemicals • Plastics • Life Sciences • Packaging • Building Materials • Security
 Electronics • Industrial Components & Equipment • Automotive & Transportation
 Equipment • Household Goods • Energy/Power Equipment

Click here to learn more about Freedonia

Freedonia Custom Research

Freedonia Custom Research delivers the same high quality, thorough and unbiased assessment of an industry or market as an industry study. Since the research initiative is based upon a company's specific needs, companies harness Freedonia's research capabilities and resources to answer unique questions. When you leverage the results of a Freedonia Custom Research engagement, you are able to obtain important answers to specific questions and issues associated with: mergers and acquisitions, new product launches/development, geographic expansion, entry into new markets, strategic business planning, and investment and funding decisions.

Freedonia Custom Research is ideal for companies seeking to make a strategic difference in the status quo and focus on future business growth. Working side by side with clients, Freedonia's team is able to define a research project that is custom-tailored to answer specific questions and provide the basis from which a company can make informed business decisions.



Click here for complete title list

Click here to learn more about Custom Research



Click here to visit freedoniagroup.com